A Killer Flu?

Examines shortfalls in available anti-viral medication and hospital capacity to respond to an epidemic, compares U.S. preparedness to that of the United Kingdom and Canada, and offers recommendations designed to boost America's preparedness

The Sweeping Changes Felt in Healthcare During the Covid-19 Pandemic

This paper aims to acknowledge frontline healthcare workers’ obstacles and hospitals’ hardships during the covid pandemic in 2020. After identifying the origin and epidemiology of the covid-19 virus, extensive research determined how challenges impacted global hospitals. These challenges included reduction of staff, supply shortages, changes in policies and procedures, organizational forced mandates, decreased revenue, hospital capacity overflow, hospital visitation guidelines, fears among healthcare professionals leading to psychological distress, and management of the unknown virus within healthcare organizations worldwide. The research will discuss healthcare mandates that took place to manage the covid virus, visitation guidelines hospitals adopted during the Covid-19 pandemic to reduce transmission, how healthcare management supported staff, and how healthcare organizations ensured the safety of patients, staff, and visitors. It will illustrate how medical facilities have quickly adapted to meet the demands of a national crisis. This project will identify how the pandemic resulted in distress and created a negative psychological impact leading to burnout among healthcare staff. My research includes personal interviews with frontline healthcare workers who experienced the trauma firsthand. They discuss the hardships they experienced during that time. It discusses the healthcare staff\u27s psychological significance during the covid-19 pandemic and the significance of frontline staff support from administration, leadership, colleagues, and family during the crisis. Finally, the paper provides modifications for new workflow processes adopted by healthcare staff to meet the demands initiated by the disease. This project aims to provide extensive research on how healthcare workers experienced changes in workflow during Covid-19 and how they maintained a healthy culture within our healthcare systems, and how hospitals are still trying to come back from this challenging time. Healthcare staff must be recognized and advocated globally for risking their health to care for those critically ill with the covid-19 virus

Obstacles to pH1N1 Vaccine Availability: the Complex Contracting Relationship between Vaccine Manufacturers, WHO, Donor and Beneficiary Governments

Vaccines are the most important line of defense to protect public health and the spread of disease during influenza pandemics. Yet the 2009 experience with pandemic H1N1 influenza showed that manufacturers, wealthy and poor governments were completely unprepared for the demands that global demand for vaccine production and distribution might impose. This chapter analyzes the failures of the system in 2009-10 with the aim of facilitating greater preparedness for future influenza pandemics

The disease of corruption: views on how to fight corruption to advance 21st century global health goals

Corruption has been described as a disease. When corruption infiltrates global health, it can be particularly devastating, threatening hard gained improvements in human and economic development, international security, and population health. Yet, the multifaceted and complex nature of global health corruption makes it extremely difficult to tackle, despite its enormous costs, which have been estimated in the billions of dollars. In this forum article, we asked anti-corruption experts to identify key priority areas that urgently need global attention in order to advance the fight against global health corruption. The views shared by this multidisciplinary group of contributors reveal several fundamental challenges and allow us to explore potential solutions to address the unique risks posed by health-related corruption. Collectively, these perspectives also provide a roadmap that can be used in support of global health anti-corruption efforts in the post-2015 development agenda

Ready or Not? Protecting the Public's Health From Diseases, Disasters, and Bioterrorism, 2009

Based on ten indicators, assesses progress in the readiness of states, federal government, and hospitals to respond to public health emergencies, with a focus on the H1N1 flu. Outlines improvements and concerns in funding, accountability, and other areas

Vaccines are not yet a silver bullet: The imperative of continued communication about the importance of COVID-19 safety measures

COVID-19 vaccines are by no means a silver bullet. With more COVID-19 vaccines expecting approval in the coming months, it is necessary to note that vaccine availability does not equate to vaccine accessibility, nor vaccine efficacy. Some research suggests that approximately 9 out of 10 individuals living in lower-income countries will not have access to COVID-19 vaccines until 2023 or later. For higher-income countries, such as the United States, the prevalence of vaccine hesitancy may further compound the situation. These insights combined, in turn, emphasize the fact that even though COVID-19 vaccines are becoming more available, safety measures (e.g., face masks, personal hygiene, and social distancing) are still of pivotal importance in protecting personal and public health against COVID-19. Furthermore, this paper argues for the continued imperative for health experts and government officials to communicate and emphasize the importance of COVID-19 safety measures with the public, to make sure people are protected against COVID-19 till the pandemic ceases to pose a threat to personal or public health

Literature review: The vaccine supply chain

Vaccination is one of the most effective ways to prevent and/or control the outbreak of infectious diseases. This medical intervention also brings about many logistical questions. In the past years, the Operations Research/Operations Management community has shown a growing interest in the logistical aspects of vaccination. However, publications on vaccine logistics often focus on one specific logistical aspect. A broader framework is needed so that open research questions can be identified more easily and contributions are not overlooked.In this literature review, we combine the priorities of the World Health Organization for creating a flexible and robust vaccine supply chain with an Operations Research/Operations Management supply chain perspective. We propose a classification for the literature on vaccine logistics to structure this relatively new field, and identify promising research directions. We classify the literature into the following four components: (1) product, (2) production, (3) allocation, and (4) distribution. Within the supply chain classification, we analyze the decision problems for existing outbreaks versus sudden outbreaks and developing countries versus developed countries. We identify unique characteristics of the vaccine supply chain: high uncertainty in both supply and demand; misalignment of objectives and decentralized decision making between supplier, public health organization and end customer; complex political decisions concerning allocation and the crucial

Patent Landscape of Influenza A Virus Prophylactic Vaccines and Related Technologies

Executive Summary: This report focuses on patent landscape analysis of technologies related to prophylactic vaccines targeting pandemic strains of influenza. These technologies include methods of formulating vaccine, methods of producing of viruses or viral subunits, the composition of complete vaccines, and other technologies that have the potential to aid in a global response to this pathogen. The purpose of this patent landscape study was to search, identify, and categorize patent documents that are relevant to the development of vaccines that can efficiently promote the development of protective immunity against pandemic influenza virus strains. The search strategy used keywords which the team felt would be general enough to capture (or “recall”) the majority of patent documents which were directed toward vaccines against influenza A virus. After extensive searching of patent literature databases, approximately 33,500 publications were identified and collapsed to about 3,800 INPADOC families. Relevant documents, almost half of the total, were then identified and sorted into the major categories of vaccine compositions (about 570 families), technologies which support the development of vaccines (about 750 families), and general platform technologies that could be useful but are not specific to the problems presented by pandemic influenza strains (about 560 families). The first two categories, vaccines and supporting technologies, were further divided into particular subcategories to allow an interested reader to rapidly select documents relevant to the particular technology in which he or she is focused. This sorting process increased the precision of the result set. The two major categories (vaccines and supporting technologies) were subjected to a range of analytics in order to extract as much information as possible from the dataset. First, patent landscape maps were generated to assess the accuracy of the sorting procedure and to reveal the relationships between the various technologies that are involved in creating an effective vaccine. Then, filings trends are analyzed for the datasets. The country of origin for the technologies was determined, and the range of distribution to other jurisdictions was assessed. Filings were also analyzed by year, by assignee, and by inventor. Finally, the various patent classification systems were mapped to find which particular classes tend to hold influenza vaccine-related technologies. Besides the keywords developed during the searches and the landscape map generation, the classifications represent an alternate way for further researchers to identify emerging influenza technologies. The analysis included creation of a map of keywords, as shown above, describing the relationship of the various technologies involved in the development of prophylactic influenza A vaccines. The map has regions corresponding to live attenuated virus vaccines, subunit vaccines composed of split viruses or isolated viral polypeptides, and plasmids used in DNA vaccines. Important technologies listed on the map include the use of reverse genetics to create reassortant viruses, the growth of viruses in modified cell lines as opposed to the traditional methods using eggs, the production of recombinant viral antigens in various host cells, and the use of genetically-modified plants to produce virus-like particles. Another major finding was that the number of patent documents related to influenza being published has been steadily increasing in the last decade, as shown in the figure below. Until the mid-1990s, there were only a few influenza patent documents being published each year. The number of publications increased noticeably when TRIPS took effect, resulting in publication of patent applications. However, since 2006 the number of vaccine publications has exploded. In each of 2011 and 2012, about 100 references disclosing influenza vaccine technologies were published. Thus, interest in developing new and more efficacious influenza vaccines has been growing in recent years. This interest is probably being driven by recent influenza outbreaks, such as the H5N1 (bird flu) epidemic that began in the late 1990s and the 2009 H1N1 (swine flu) pandemic. The origins of the vaccine-related inventions were also analyzed. The team determined the country in which the priority application was filed, which was taken as an indication of the country where the invention was made or where the inventors intended to practice the invention. By far, most of the relevant families originated with patent applications filed in the United States. Other prominent priority countries were the China and United Kingdom, followed by Japan, Russia, and South Korea. France was a significant priority country only for supporting technologies, not for vaccines. Top assignees for these families were mostly large pharmaceutical companies, with the majority of patent families coming from Novartis, followed by GlaxoSmithKline, Pfizer, U.S. Merck (Merck, Sharpe, & Dohme), Sanofi, and AstraZeneca. Governmental and nonprofit institutes in China, Japan, Russia, South Korea and the United States also are contributing heavily to influenza vaccine research. Lastly, the jurisdictions were inventors have sought protection for their vaccine technologies were determined, and the number of patent families filing in a given country is plotted on the world map shown on page seven. The United States, Canada, Australia, Japan, South Korea and China have the highest level of filings, followed by Germany, Brazil, India, Mexico and New Zealand. However, although there are a significant number of filings in Brazil, the remainder of Central and South America has only sparse filings. Of concern, with the exception of South Africa, few other African nations have a significant number of filings. In summary, the goal of this report is to provide a knowledge resource for making informed policy decisions and for creating strategic plans concerning the assembly of efficacious vaccines against a rapidly-spreading, highly virulent influenza strain. The team has defined the current state of the art of technologies involved in the manufacture of influenza vaccines, and the important assignees, inventors, and countries have been identified. This document should reveal both the strengths and weaknesses of the current level of preparedness for responding to an emerging pandemic influenza strain. The effects of H5N1 and H1N1 epidemics have been felt across the globe in the last decade, and future epidemics are very probable in the near future, so preparations are necessary to meet this global health threat

Literature Review - the vaccine supply chain

Vaccination is one of the most effective ways to prevent the outbreak of an infectious disease. This medical intervention also brings about many logistical quest

Ready or Not? Protecting the Public's Health in the Age of Bioterrorism, 2004

Examines ten key indicators to evaluate state preparedness to respond to bioterrorist attacks and other public health emergencies. Evaluates the federal government's role and performance, and offers recommendations for improving readiness